1
|
Pandya PA, Shah PA, Shrivastav PS. Application of supercritical fluid chromatography for separation and quantitation of 15 co-formulated binary anti-hypertensive medications using a single elution protocol. Biomed Chromatogr 2020; 35:e5035. [PMID: 33226650 DOI: 10.1002/bmc.5035] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2020] [Revised: 11/17/2020] [Accepted: 11/20/2020] [Indexed: 11/05/2022]
Abstract
A facile supercritical fluid chromatography method is proposed to analyse 15 co-formulated binary anti-hypertensive drug combinations using a customized elution procedure. The effect of mobile phase composition, column back pressure and temperature was suitably optimized for adequate retention, analyte response and resolution. The chromatographic separation of the different drug combinations was performed on a DCPak poly(4-vinylpyridine) column (250 × 4.6 mm, 5 μm) at 125-bar pressure and 40°C using a photodiode array detector. A linear gradient of CO2 and 0.1% formic acid in methanol provided the best elution conditions for all drug combinations. Baseline separation of the drugs was possible with resolution factor Rs ranging from 1.42 to 12.58. The method was validated for specificity, sensitivity, accuracy and precision, recovery and robustness. The limit of detection and limit of quantitation for aliskiren, amlodipine, atenolol, candesartan, hydrochlorothiazide, lisinopril, losartan, metoprolol, olmesartan, telmisartan and valsartan were in the range of 0.26-2.56 and 0.77-7.75 μg/mL, respectively. The thermodynamic study revealed that interactions of the drugs with the stationary phase were spontaneous as evident from the negative free energy values, and the separation process was enthalpy driven. The developed method was successfully employed to analyse these drugs in their co-formulated tablet formulations.
Collapse
Affiliation(s)
- Pranav A Pandya
- Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, India
| | - Priyanka A Shah
- Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, India
| | - Pranav S Shrivastav
- Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, India
| |
Collapse
|
2
|
Ghanbari K, Sivandi A. Development of a Novel Nanocomposite Based on Reduced Graphene Oxide/Chitosan/Au/ZnO and Electrochemical Sensor for Determination of Losartan. CURR ANAL CHEM 2020. [DOI: 10.2174/1573411016666191218161500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Hypertension is a major risk for morbidity and mortality, while hypertension
is associated with cardiovascular disease and organ damage. Recent research efforts have focused
on the development of highly selective angiotensin receptor blockers. In which losartan (LOS)
is considered as a new generation of an effective oral drug product against arterial hypertension.
Therefore, the determination of drugs in biological fluids, pharmaceuticals (tablets), and wastewater
is of critical importance for clinical applications, forensics, quality control, and environmental
protection that call for the development of analytical methods. Many ranges of methods such as spectroscopic
methods and chromatographic techniques have been developed to determine LOS in pharmaceutical
formulations and biological fluids. However, there are crucial interference problems in
these methods. For these reasons, more sensitive, desirable, portable, low-cost, simple, and selective
nanocomposite-based sensors are needed in terms of health safety. Nanomaterials such as reduced
graphene oxide, chitosan, and metal nanoparticles are used to improve the sensitivity in the
development of electrochemical sensors.
Objective:
In this study, a novel reduced graphene oxide (RGO), chitosan (Chit), gold (Au), and zinc
oxide (ZnO) nanocomposite (RGO/Chitosan/Au/ZnO) was synthesized and used to develop a sensitive
and efficient electrochemical sensor for LOS detection.
Methods:
Modification of electrode by RGO/Chit/Au/ZnO nanocomposite was performed in four
stages with GO (at -2.0 V for 150 s), Chitosan (at -3.0 V for 300 s), Au nanoparticles (at -0.4 V for
400 s), and Zn nanoflowers like (at -0.7 V for 1200 s). The RGO/Chitosan/Au/ZnO nanocomposite
was characterized by field emission scanning electron microscopy (FE-SEM), X-ray diffraction
(XRD), X-ray photoelectron spectroscopy (XPS), Fourier transform infrared spectroscopy (FT-IR).
Cyclic Voltammetry (CV) and Differential Pulse Voltammetry (DPV) were used to detect LOS, and
the influence of pH value, scan rate, accumulation potential, and time also losartan concentration on
the performance of ZnO/Au/Chitosan/RGO/GCE were investigated. In order to investigate the selectivity
of the modified electrode for the determination of LOS, the effect of possible interfering
species was evaluated and showed that these species are not interferences. Also, the reproducibility
of the modified electrode was investigated and implying that the RGO/Chit/Au/ZnO nanocomposite
was highly reproducible.
Results:
The modified electrode was used as a sensor for the selective and sensitive determination of
LOS with a detection limit of 0.073 μM over the dynamic linear range of 0.5μM to 18.0 μM. In
addition, electrochemical oxidation of LOS was well recovered in pharmaceutical formulations.
Conclusion:
LOS is used to treat high blood pressure, taking into account the oxidation of this
compound, the use of electrochemical based sensors, ideally suited to a specific chemical species,
can be fully selectable and High-sensitivity answer is very important. In this study, the electrodes
with RGO/Chit/Au/ZnO nanocomposite were modified by the electrochemical method.
Nanocomposites were characterized by various methods such as FE-SEM, FT-IR, XRD, Raman, and
XPS. The electrocatalytic activity of the modified electrode was then investigated for measuring
LOS. According to the results of the modified electrode, high sensitivity, reproducibility, and
selectivity have been shown to oxidize this composition.
Collapse
Affiliation(s)
- Khadijeh Ghanbari
- Department of Chemistry, Faculty of Physics and Chemistry, School of Science, Alzahra University, Vanak, Tehran 1993891167, Iran
| | - Ashraf Sivandi
- Department of Chemistry, Faculty of Physics and Chemistry, School of Science, Alzahra University, Vanak, Tehran 1993891167, Iran
| |
Collapse
|
3
|
Pelouch R, Voříšek V, Furmanová V, Solař M. The Assessment of Serum Drug Levels to Diagnose Non-Adherence in Stable Chronic Heart Failure Patients. ACTA MEDICA (HRADEC KRÁLOVÉ) 2019; 62:52-57. [DOI: 10.14712/18059694.2019.46] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Background: The aim of our study was to evaluate the prevalence of drug non-adherence in stable chronic heart failure (CHF) patients using serum drug levels (SDL) assessment. Methods: CHF patients were prospectively enrolled during scheduled outpatient visit. Except standard procedures an unanticipated blood sampling for the SDL assessment was obtained. Analysis was focused on the prescribed heart failure and antihypertensive medication and was performed by liquid chromatography coupled with mass spectrometry. The patient was labelled as non-adherent if at least one of drugs assessed was not found in the serum. In the first half of patients multiple SDL have been evaluated during the follow-up. Results: Eighty one patients were enrolled. The non-adherence was proven in twenty of them (25%). In the subgroup of thirty eight patients with multiple SDL evaluation the non-adherence raised significantly with increasing number of visits assessed together (21% for single visit, 29% for two of three visits assessed together and 34% for all three visits evaluated together, all p < 0.001). Conclusion: The non-adherence was proven in significant part of stable CHF patients using SDL assessment. This method seems to be reliable and effective and should be a part of clinical assessment in selected patients with CHF.
Collapse
|
4
|
Babarahimi V, Talebpour Z, Haghighi F, Adib N, Vahidi H. Validated determination of losartan and valsartan in human plasma by stir bar sorptive extraction based on acrylate monolithic polymer, liquid chromatographic analysis and experimental design methodology. J Pharm Biomed Anal 2018; 153:204-213. [DOI: 10.1016/j.jpba.2018.02.030] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Revised: 02/11/2018] [Accepted: 02/13/2018] [Indexed: 12/29/2022]
|
5
|
Vespasiano CFP, Laurito TL, Iwamoto RD, Moreno RA, Mendes GD, De Nucci G. Bioequivalence study between a fixed-dose single-pill formulation of nebivolol plus hydrochlorothiazide and separate formulations in healthy subjects using high-performance liquid chromatography coupled to tandem mass spectrometry. Biomed Chromatogr 2016; 31. [PMID: 27809345 DOI: 10.1002/bmc.3884] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 09/19/2016] [Accepted: 10/28/2016] [Indexed: 11/10/2022]
Abstract
Systemic arterial hypertension is a major risk factor for cerebrovascular disease. Therefore, adequate control of blood pressure is of enormous importance. One of the many fixed-dose single-pill antihypertensive formulations available on the market is the combination of nebivolol and hydrochlorothiazide. The objective of this study was to develop two distinct high-performance liquid chromatography coupled to tandem mass spectrometry methods to simultaneously quantify nebivolol and hydrochlorothiazide in human plasma. The methods were employed in a bioequivalence study, the first assay involving a nebivolol fixed-dose single-pill formulation based on healthy Brazilian volunteers. Nebilet HCT™ (nebivolol 5 mg + hydrochlorothiazide 12.5 mg tablet, manufactured by Menarini) was the test formulation. The reference formulations were Nebilet™ (nebivolol 5 mg tablet, manufactured by Menarini) and Clorana™ (hydrochlorothiazide 25 mg tablet, manufactured by Sanofi). For both analytes, liquid-liquid extraction was employed for sample preparation and the chromatographic run time was 3.5 min. The limits of quantification validated were 0.02 ng/mL for nebivolol and 1 ng/mL for hydrochlorothiazide. Since the 90% CI for Cmax , AUC(0-last) and AUC(0-inf) individual test/reference ratios were within the 80-125% interval indicative of bioequivalence, it was concluded that Nebilet HCT™ is bioequivalent to Nebilet™ and Clorana™.
Collapse
Affiliation(s)
| | | | | | - Ronilson Agnaldo Moreno
- Galeno Research Unit, Campinas, SP, Brazil.,Faculty of Health Sciences of Barretos, Barretos, Brazil
| | - Gustavo D Mendes
- State University of Campinas, Campinas, SP, Brazil.,Galeno Research Unit, Campinas, SP, Brazil.,University Camilo Castelo Branco, São Paulo, SP, Brazil
| | - Gilberto De Nucci
- State University of Campinas, Campinas, SP, Brazil.,Galeno Research Unit, Campinas, SP, Brazil.,University Camilo Castelo Branco, São Paulo, SP, Brazil
| |
Collapse
|
6
|
Moon SJ, Kim SY, Lim CH, Jang HB, Kim MG, Jeon JY. Phase 1 and Pharmacokinetic Drug-Drug Interaction Study of Metformin, Losartan, and Linagliptin Coadministered With DW1029M in Healthy Volunteers. Clin Pharmacol Drug Dev 2016; 6:408-419. [PMID: 27739231 DOI: 10.1002/cpdd.320] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Accepted: 10/05/2016] [Indexed: 12/25/2022]
Abstract
We investigated botanical drug-pharmaceutical drug interactions between DW1029M (a botanical extract of Morus alba linne root bark and Puerariae radix) and metformin, losartan, and linagliptin in the steady state. Three studies were conducted as randomized, open-label, 2-period, 2-treatment, multiple-dose, 2-way crossover designs. Eligible subjects received metformin (500 mg twice daily), losartan (50 mg once daily), or linagliptin (5 mg once daily) with DW1029M (300 mg × 2T twice daily) every 12 hours on days 1 through 6 and a single dose on the morning of day 7. Coadministration of DW1029M with metformin, losartan, or linagliptin had no clinically relevant effects based on the area under the plasma concentration-time curve (AUCτ ) geometric least-squares mean ratio (GMR) - AUCτ GMR, 89.7; 90% confidence interval (CI), 81.0-99.4 for metformin; AUCτ GMR, 96.2; 90%CI, 86.3-107.1 for losartan; and AUCτ GMR, 89.7; 90%CI, 83.2-96.6 for linagliptin. In addition, coadministration of DW1029M did not have any clinically meaningful effect on the maximum plasma concentration (Cmax,ss ) - Cmax,ss GMR, 87.3; 90%CI, 76.2-100.0 for metformin; Cmax,ss GMR, 90.5; 90%CI, 78.3-104.6 for losartan; and Cmax,ss GMR, 81.4; 90%CI, 69.5-95.3 for linagliptin. Coadministration of DW1029M with metformin, losartan, or linagliptin was well tolerated.
Collapse
Affiliation(s)
- Seol Ju Moon
- Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea
| | - Sun-Young Kim
- Center for Clinical Pharmacology and Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Republic of Korea
| | - Cheol-Hee Lim
- Department of Pharmacology, College of Medicine, Chung-ang University, Seoul, Republic of Korea.,Dongwha Pharmaceuticals Project Team, Seoul, Republic of Korea
| | - Hwan Bong Jang
- Dongwha Pharmaceuticals Project Team, Seoul, Republic of Korea
| | - Min-Gul Kim
- Center for Clinical Pharmacology and Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Republic of Korea.,Department of Pharmacology, School of Medicine, Chonbuk National University, Jeonju, Republic of Korea
| | - Ji-Young Jeon
- Center for Clinical Pharmacology and Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Republic of Korea
| |
Collapse
|
7
|
Serum drug levels to diagnose non-adherence in acute decompensated heart failure. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; 160:244-7. [PMID: 27277159 DOI: 10.5507/bp.2016.031] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Accepted: 05/27/2016] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND The aim of this study was to analyze medication non-adherence by measuring serum drug levels (SDL) in patients presenting with acute decompensated heart failure (ADHF). METHODS Included in the study were chronic heart failure patients presenting with signs of acute decompensation. Blood sampling for the measurement of SDL was performed shortly after presentation. SDL were measured using liquid chromatography coupled with mass spectrometry. The estimation of SDL was calculated from the recommended chronic cardiac medications with the exception of drugs administered as part of the acute treatment prior to blood sampling. The patients were labeled as non-adherent when any one of the evaluated medications was not found in the serum. RESULTS Fifty patients with ADHF were prospectively enrolled. All of the evaluated drugs were detected in the sera of 28 (56%) patients. Non-adherence was diagnosed in the remaining 22 (44%) patients. None of the evaluated medications was detected in the sera of 5 (10%) patients. CONCLUSION The estimation of SDL indicates that non-adherence to the recommended chronic therapy is a common problem among patients presenting with ADHF. This method should be an essential aspect of routine clinical evaluation in these patients.
Collapse
|
8
|
Structure–response relationship in electrospray ionization-mass spectrometry of sartans by artificial neural networks. J Chromatogr A 2016; 1438:123-32. [DOI: 10.1016/j.chroma.2016.02.021] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Revised: 01/17/2016] [Accepted: 02/04/2016] [Indexed: 11/23/2022]
|
9
|
Meimaroglou S, Vonaparti A, Migias G, Gennimata D, Poulou S, Panderi I. Direct injection human plasma analysis for the quantification of antihypertensive drugs for therapeutic drug monitoring using hydrophilic interaction liquid chromatography/electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 1004:1-9. [DOI: 10.1016/j.jchromb.2015.09.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2015] [Revised: 08/31/2015] [Accepted: 09/02/2015] [Indexed: 11/26/2022]
|
10
|
Munger MA, Hadlock G, Stoddard G, Slawson MH, Wilkins DG, Cox N, Rollins D. Assessing orally bioavailable commercial silver nanoparticle product on human cytochrome P450 enzyme activity. Nanotoxicology 2014; 9:474-81. [PMID: 25137296 DOI: 10.3109/17435390.2014.948092] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Nanotechnology produces a wide range of medicinal compounds, including nanoparticulate silver, which are increasingly introduced in various forms for consumer use. As with all medicinal compounds, potential drug interactions are an important consideration for ingested silver nanoparticles. Nanoparticulate silver-drug interactions may be mediated through induced oxidative stress in liver tissue where the majority of systemically bioavailable silver nanoparticles is found. To investigate whether an orally ingested commercially available colloidal silver nanoproduct produces pharmacokinetic interference on select cytochrome P450 enzymes, a prospective, single-blind, controlled in vivo human study using simultaneous administration of standardized probes for P450 enzyme classes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 was conducted. Oral ingestion of a commercial colloidal silver nanoproduct produces detectable silver in human serum after 14 days of dosing. This silver, however, elicits no demonstrable clinically significant changes in metabolic, hematologic, urinary, physical findings or cytochrome P450 enzyme inhibition or induction activity. Given their increasingly broad, diverse human exposures, future characterization of human cytochrome P450 enzyme activity for other systemically bioavailable nanotechnology products are warranted.
Collapse
|
11
|
Muszalska I, Sobczak A, Dołhań A, Jelińska A. Analysis of Sartans: a review. J Pharm Sci 2013; 103:2-28. [PMID: 24227012 DOI: 10.1002/jps.23760] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2013] [Revised: 10/03/2013] [Accepted: 10/03/2013] [Indexed: 11/05/2022]
Abstract
The risk of cardiovascular diseases is closely related to hypertension, high cholesterol levels, and diabetes. When these risk factors appear together they are referred to as a metabolic syndrome. In the treatment of cardiovascular diseases, a combination of antihypertensive, hypolipemiant, and antidiabetic drugs is often applied. Diuretics (chlortalidone, hydrochlorothiazide, etc.) and angiotensin II receptors antagonist (sartans) are used to control hypertension, whereas statins (fluvastatin, simvastatin, etc.) are used to reduce cholesterol levels. This review is concerned with methods for the analysis of sartans in various matrices, such as pharmaceutical formulations, environmental and biological samples, and discusses the current status of stability studies of sartans . It also presents analytical methods for the simultaneous determination of sartans, diuretics, and statins.
Collapse
Affiliation(s)
- Izabela Muszalska
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, Grunwaldzka 6, Poznań, 60-780, Poland
| | | | | | | |
Collapse
|
12
|
Lv CM, Wei CM, Bu FL, Chen R, Wang XL, Li R, Wang BJ, Guo RC. Determination of Amlodipine in Human Plasma by LC-MS/MS and Its Bioequivalence Study in Healthy Chinese Subjects. ACTA ACUST UNITED AC 2013. [DOI: 10.4236/pp.2013.42027] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
13
|
A simple and precise conductometric method for the determination of losartan in pharmaceutical products. OPEN CHEM 2012. [DOI: 10.2478/s11532-012-0110-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
AbstractLosartan is an antihypertensive agent that lost its patent protection in 2010, and, consequently, it has been available in generic form. The latter motivated the search for a rapid and precise alternative method. Here, a simple conductometric titration in aqueous medium is described for the losartan analysis in pharmaceutical formulations. The first step of the titration occurs with the protonation of losartan producing a white precipitate and resulting in a slow increase in conductivity. When the protonation stage is complete, a sharp increase in conductivity occurs which was determined to be due to the presence of excess of acid. The titrimetric method was applied to the determination of losartan in pharmaceutical products and the results are comparable with values obtained using a chromatographic method recommended by the United States Pharmacopoeia. The relative standard deviation for successive measurements of a 125 mg L−1 (2.71×10−4 mol L−1) losartan solution was approximately 2%. Recovery study in tablet samples ranged between 99 and 102.4%. The procedure is fast, simple, and represents an attractive alternative for losartan quantification in routine analysis. In addition, it avoids organic solvents, minimizes the risk of exposure to the operator, and the waste treatment is easier compared to classical chromatographic methods.
Collapse
|
14
|
Liquid chromatography-mass spectrometric determination of losartan and its active metabolite on dried blood spots. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 902:47-54. [PMID: 22770781 DOI: 10.1016/j.jchromb.2012.06.013] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2012] [Revised: 06/08/2012] [Accepted: 06/13/2012] [Indexed: 11/21/2022]
Abstract
A simple and rapid quantitative bioanalytical liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for simultaneous determination of losartan and its active metabolite, losartan carboxylic acid on rat dried blood spots was developed and validated as per regulatory guidelines. Losartan and its metabolite were extracted from dried blood spots using 50% aqueous methanol and separated on Waters XTerra(®) RP18 (250 mm × 4.6 mm, 5 μm) column using mobile phase composed of 40% acetonitrile and 60% aqueous ammonium acetate (10mM). The eluents were monitored using ESI tandem mass spectrometric detection with negative polarity in MRM mode using ion transitions m/z 421.2→179.0, m/z 435.3→157.0 and m/z 427.3→193.0 for losartan, losartan carboxylic acid and Irbesartan (internal standard), respectively. The method was validated over the linear range of 1-200 ng/mL and 5-1000 ng/mL with lower limits of quantification of 1.0 ng/mL and 5.0 ng/mL for losartan and losartan carboxylic acid, respectively. Inter and intra-day precision and accuracy (Bias) were below 5.96% and between -2.8 and 1.5%, respectively. The mean recoveries of the analytes from dried blood spots were between 89% and 97%. No significant carry over and matrix effects were observed. The stability of stock solution, whole blood, dried blood spot and processed samples were tested under different conditions and the results were found to be well within the acceptable limits. Additional validation parameters such as influence of hematocrit and spot volume were also evaluated and found to be well within the acceptable limits.
Collapse
|
15
|
Okawada M, Koga H, Larsen SD, Showalter HD, Turbiak AJ, Jin X, Lucas PC, Lipka E, Hillfinger J, Kim JS, Teitelbaum DH. Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis. Dig Dis Sci 2011; 56:2553-65. [PMID: 21399927 PMCID: PMC3163034 DOI: 10.1007/s10620-011-1651-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2010] [Accepted: 02/16/2011] [Indexed: 12/15/2022]
Abstract
BACKGROUND Renin-angiotensin system blockade reduces inflammation in several organ systems. Having found a fourfold increase in angiotensin II type Ia receptor expression in a dextran sodium sulfate colitis model, we targeted blockade with angiotensin II type Ia receptor antagonists to prevent colitis development. Because hypotension is a major complication of angiotensin II type Ia receptor antagonists use, we hypothesized that use of angiotensin II type Ia receptor antagonists compounds which lack cell membrane permeability, and thus enteric absorption, would allow for direct enteral delivery at far higher concentrations than would be tolerated systemically, yet retain efficacy. METHODS Based on the structure of the angiotensin II type Ia receptor antagonist losartan, deschloro-losartan was synthesized, which has extremely poor cell membrane permeability. Angiotensin II type Ia receptor antagonist efficacy was evaluated by determining the ability to block NF-κB activation in vitro. Dextran sodium sulfate colitis was induced in mice and angiotensin II type Ia receptor antagonist efficacy delivered transanally was assessed. RESULTS In vitro, deschloro-losartan demonstrated near equal angiotensin II type Ia receptor blockade compared to losartan as well as another angiotensin II type Ia receptor antagonist, candesartan. In the dextran sodium sulfate model, each compound significantly improved clinical and histologic scores and epithelial cell apoptosis. Abundance of TNF-α, IL-1β, and IL6 mRNA were significantly decreased with each compound. In vitro and in vivo intestinal drug absorption, as well as measures of blood pressure and mucosal and colonic blood flow, showed significantly lower uptake of deschloro-losartan compared to losartan and candesartan. CONCLUSIONS This study demonstrated efficacy of high-dose angiotensin II type Ia receptor antagonists in this colitis model. We postulate that a specially designed angiotensin II type Ia receptor antagonist with poor oral absorption may have great potential as a new therapeutic agent for inflammatory bowel disease in the future.
Collapse
Affiliation(s)
- Manabu Okawada
- Section of Pediatric Surgery, Department of Surgery, The University of Michigan Medical School, Mott Children’s Hospital, F3970, Ann Arbor, MI 48109-0245, USA
| | - Hiroyuki Koga
- Section of Pediatric Surgery, Department of Surgery, The University of Michigan Medical School, Mott Children’s Hospital, F3970, Ann Arbor, MI 48109-0245, USA
| | - Scott D. Larsen
- Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109-1065, USA
| | - Hollis D. Showalter
- Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109-1065, USA
| | - Anjanette J. Turbiak
- Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109-1065, USA
| | - Xiaohong Jin
- Department of Pathology, The University of Michigan Medical School, Ann Arbor, MI 48109, USA
| | - Peter C. Lucas
- Department of Pathology, The University of Michigan Medical School, Ann Arbor, MI 48109, USA
| | - Elke Lipka
- Therapeutic Systems Research Laboratories, Inc, Ann Arbor, MI 48108, USA
| | - John Hillfinger
- Therapeutic Systems Research Laboratories, Inc, Ann Arbor, MI 48108, USA
| | - Jae Seung Kim
- Therapeutic Systems Research Laboratories, Inc, Ann Arbor, MI 48108, USA
| | - Daniel H. Teitelbaum
- Section of Pediatric Surgery, Department of Surgery, The University of Michigan Medical School, Mott Children’s Hospital, F3970, Ann Arbor, MI 48109-0245, USA
| |
Collapse
|
16
|
Coudoré F, Harvard L, Lefeuvre S, Billaud EM, Beaune P, Bobrie G, Azizi M, Prognon P, Laurent S. HPLC–DAD Analysis of Hydrochlorothiazide and Irbesartan in Hypertensive Patients on Fixed-Dose Combination Therapy. Chromatographia 2011. [DOI: 10.1007/s10337-011-2111-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Moussa B, Mohamed M, Youssef N. Simultaneous densitometric TLC analysis of olmesartan medoxomil and hydrochlorothiazide in the tablet dosage form. JPC-J PLANAR CHROMAT 2011. [DOI: 10.1556/jpc.24.2011.1.6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
18
|
Jia JY, Zhang MQ, Liu YM, Liu Y, Liu GY, Li SJ, Lu C, Weng LP, Qi YL, Yu C. Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. Clin Ther 2010; 32:1387-95. [PMID: 20678685 DOI: 10.1016/j.clinthera.2010.06.018] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/12/2010] [Indexed: 11/24/2022]
Abstract
BACKGROUND Losartan is a nonpeptide angiotensin II receptor antagonist used as an antihypertensive agent. The relative bioavailability of a newly developed tablet compared with an established branded formulation has not been reported in a Chinese population. OBJECTIVE To meet the requirements for marketing a new generic product, the study was designed to compare the pharmacokinetic parameters and relative bioavailability of a new generic losartan potassium 50-mg tablet (test formulation) with a branded 50-mg tablet (reference formulation) in healthy Chinese male volunteers. METHODS A single-dose, randomized-sequence, openlabel, 2-way crossover study was conducted in healthy Chinese male volunteers. Eligible participants were randomly assigned in a 1:1 ratio to receive a single 50-mg tablet of the test or reference formulation, followed by a 1-week washout period and then administration of the alternate formulation. The study drugs were administered after a 10-hour overnight fast. Plasma samples were collected over 36 hours. Tolerability was evaluated by recording adverse events (AEs) and monitoring vital signs, ECGs, and laboratory tests at baseline and at completion of the study. Plasma concentrations of losartan and its active metabolite (EXP3174) were analyzed by LC-MS/MS. Pharmacokinetic parameters, including C(max), AUC(0-36), and AUC(0-infinity), were calculated. If the 90% CIs for the log-transformed values of AUC were within 80% to 125%, and that of C(max) was within 70% to 143%, the 2 products would be considered bioequivalent according to the guidelines of the US Food and Drug Administration and the State Food and Drug Administration of China. RESULTS Twenty-seven healthy Chinese male volunteers participated in this study (mean [SD] age, 24.5 [2.3] years [range, 20-29 years]; weight, 64.6 [4.0] kg [range, 60.0-75.0 kg]; height, 172.2 [4.8] cm [range, 165.0183.0 cm]; and body mass index, 21.8 [1.2] kg/m(2) [range, 20.0-25.0 kg/m(2)]). One volunteer (3.7%) experienced an AE (microscopic hematuria) after administration of the test formulation. This resolved spontaneously after 10 days and was considered by the investigator as mild; the relationship with the study drug was uncertain. No serious AEs were reported. Both formulations were associated with significant reductions in systolic and diastolic blood pressure and significant increases in heart rate compared with baseline values (all, P < 0.05). No period, formulation, or sequence effects were observed for any pharmacokinetic parameter, except for a significant subject effect. For parent losartan, the 90% CIs for the ratios (test/reference) of C(max), AUC(0-36), and AUCAUC(0-infinity) were 83.65% to 113.36%, 89.79% to 98.25%, and 90.95% to 99.55%, respectively. For the metabolite EXP3174, the 90% CIs for the ratios of C(max), AUC(0-36), and AUCAUC(0-infinity) were 93.49% to 103.61%, 96.79% to 104.09%, and 97.06% to 105.83%. Both C(max) and AUC met the predetermined criteria for assuming bioequivalence. The relative bioavailability of the test formulation to the reference formulation was 93.92% for losartan and 100.40% for EXP3174. CONCLUSIONS In this small study in healthy Chinese male volunteers, a single 50-mg oral dose of a losartan potassium tablet (test formulation) met the regulatory criteria for assuming bioequivalence to the established reference formulation. Both formulations were well tolerated.
Collapse
Affiliation(s)
- Jing-Ying Jia
- Shanghai Xuhui Central Hospital, People's Republic of China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res 2010; 34:87-90. [PMID: 20882030 DOI: 10.1038/hr.2010.183] [Citation(s) in RCA: 130] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Difficult-to-control arterial hypertension is a common medical problem that may result from severe hypertensive disease or from poor adherence to the recommended medical treatment. The identification of non-adherent patients is challenging, especially when non-adherence is intentional. The current report describes the use of serum levels of prescribed antihypertensive drugs to evaluate the adherence in individuals with difficult-to-control arterial hypertension. Serum drug levels (SDLs) were evaluated by liquid chromatography with mass spectrometry. The chromatographic separation was performed on a reversed-phase column with a gradient flow of the mobile phase. The detection of analyzed substances was accomplished on a linear ion-trap mass spectrometer. The subjects were labeled as non-adherent when the serum level of at least one of the evaluated drugs was below the limit of quantification. The study used data from 84 patients with arterial hypertension who underwent SDL assessment to verify compliance with the recommended treatment. Patients who presented with uncontrolled blood pressure despite the recommended combination of at least three antihypertensives were enrolled in the analysis. Based on the evaluation of the SDLs, all of the evaluated drugs were found in the sera of 29 (34.5%) of the study patients. In the remaining 55 (65.5%) patients, non-adherence was diagnosed. None of the prescribed antihypertensive drugs was detected in the sera of the 29 (34.5%) patients. Our data suggest that an assessment of SDLs might be helpful before an extensive evaluation is initiated for difficult-to-control hypertension.
Collapse
Affiliation(s)
- Jiri Ceral
- Department of Internal Medicine, Medical Faculty Hradec Kralove Charles University Prague, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | | | | | | | | | | |
Collapse
|
20
|
Salvadori MC, Moreira RF, Borges BC, Andraus MH, Azevedo CP, Moreno RA, Borges NC. Simultaneous Determination of Losartan and Hydrochlorothiazide in Human Plasma by LC/MS/MS with Electrospray Ionization and Its Application to Pharmacokinetics. Clin Exp Hypertens 2009; 31:415-27. [DOI: 10.1080/10641960802668714] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Goswami D, Kumar A, Khuroo AH, Monif T, Thudi NR, Shrivastav VK, Dubey SK, Shingla AK, Prakash M, Mehra S. Pharmacokinetic Estimation of Losartan, Losartan Carboxylic Acid and Hydrochlorothiazide in Human Plasma by LC/MS/MS Validated Method. ACTA ACUST UNITED AC 2008. [DOI: 10.1080/10601330802600901] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
22
|
Maggio RM, Castellano PM, Kaufman TS. A multivariate approach for the simultaneous determination of losartan potassium and hydrochlorothiazide in a combined pharmaceutical tablet formulation. Anal Bioanal Chem 2008; 391:2949-55. [PMID: 18528688 DOI: 10.1007/s00216-008-2180-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2008] [Revised: 04/09/2008] [Accepted: 05/08/2008] [Indexed: 10/22/2022]
Abstract
A convenient new method for the simultaneous determination of losartan potassium and hydrochlorothiazide, with minimum sample pretreatment, is described. The procedure, based on the multivariate analysis of spectral data in the 220-274 nm region by the partial least squares algorithm, is linear in the concentration range 1.06-5.70 mg L(-1) for hydrochlorothiazide and 4.0-22.2 mg L(-1) for losartan. It is simple, rapid and robust, allowing accurate and precise results, with drug recovery rates of 99.3 and 100.4% and relative standard deviations of 1.7 and 1.0% obtained for hydrochlorothiazide and losartan, respectively. The method was applied to the simultaneous determination of both analytes in tablets, and it provided good results which were in statistical agreement with those provided by independent HPLC analyses of the samples. The method has also been successfully applied for the construction of drug dissolution profiles of a commercial pharmaceutical preparation containing both analytes.
Collapse
Affiliation(s)
- Rubén M Maggio
- Area Análisis de Medicamentos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, and Instituto de Química Rosario (IQUIR, CONICET-UNR), Suipacha 531, Rosario, S2002LRK, Argentina
| | | | | |
Collapse
|